Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.
P SchwablM MandorferS SteinerB ScheinerD ChromyM HeracTheresa A BucsicsH HaydenK Grabmeier-PfistershammerA FerlitschG OberhuberM TraunerM Peck-RadosavljevicT ReibergerPublished in: Alimentary pharmacology & therapeutics (2016)
Interferon-free therapy reduces PHT and halts histological necroinflammatory activity in the majority of HIV/HCV-coinfected patients after SVR, which may lead to re-compensation of liver function in cirrhosis. Biomarkers could identify patients with persisting hepatic necroinflammation.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- antiretroviral therapy
- hiv positive
- hiv infected
- hiv testing
- end stage renal disease
- hiv aids
- ejection fraction
- dendritic cells
- newly diagnosed
- blood pressure
- men who have sex with men
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- immune response
- south africa
- patient reported outcomes
- bone marrow
- replacement therapy